LYRA THERAPEUTICS INC's ticker is LYRA and the CUSIP is 55234L105. A total of 39 filers reported holding LYRA THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $492,480 | +6.2% | 125,954 | +11.6% | 0.00% | – |
| Q2 2023 | $463,666 | +120.2% | 112,814 | +7.7% | 0.00% | – |
| Q1 2023 | $210,584 | -34.1% | 104,768 | +3.0% | 0.00% | – |
| Q4 2022 | $319,508 | -32.6% | 101,754 | +7.5% | 0.00% | – |
| Q3 2022 | $474,000 | -14.0% | 94,630 | -3.0% | 0.00% | – |
| Q2 2022 | $551,000 | +67.0% | 97,519 | +18.6% | 0.00% | – |
| Q1 2022 | $330,000 | -9.8% | 82,200 | -2.0% | 0.00% | – |
| Q4 2021 | $366,000 | -63.7% | 83,840 | -24.1% | 0.00% | – |
| Q3 2021 | $1,008,000 | +304.8% | 110,511 | +256.6% | 0.00% | – |
| Q2 2021 | $249,000 | -33.4% | 30,987 | -4.3% | 0.00% | – |
| Q1 2021 | $374,000 | +52.0% | 32,364 | +49.5% | 0.00% | – |
| Q4 2020 | $246,000 | +16.0% | 21,648 | +14.5% | 0.00% | – |
| Q3 2020 | $212,000 | -83.2% | 18,902 | -83.0% | 0.00% | – |
| Q2 2020 | $1,259,000 | – | 110,990 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 1,100,852 | $12,550,000 | 16.38% |
| Soleus Capital Management, L.P. | 456,138 | $5,199,000 | 0.69% |
| Ikarian Capital, LLC | 815,364 | $9,295,000 | 0.41% |
| Perceptive Advisors | 3,222,561 | $36,737,000 | 0.39% |
| Affinity Asset Advisors, LLC | 50,000 | $570,000 | 0.30% |
| RA Capital Management | 815,849 | $9,301,000 | 0.13% |
| ArrowMark Colorado Holdings LLC | 775,888 | $8,845,000 | 0.07% |
| BOOTHBAY FUND MANAGEMENT, LLC | 87,353 | $996,000 | 0.04% |
| Altium Capital Management LP | 5,218 | $59,000 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 49,000 | $559,000 | 0.01% |